BGLC - CIK 0001737523
BioNexus Gene Lab Corp (BGLC) reported net income of -$2.98M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$2.98M | -86.7% |
| FY 2024 | -$1.60M | +39.2% |
| FY 2023 | -$2.63M | -638.6% |
| FY 2022 | -$355.97K | -147.4% |
| FY 2021 | $751.57K | -31.3% |
| FY 2020 | $1.09M | +543.9% |
| FY 2019 | -$246.47K | -1031.7% |
| FY 2018 | $26.45K | - |
BioNexus Gene Lab Corp (BGLC) reported net income of -$2.98M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, BioNexus Gene Lab Corp's net income declined from $26.45K to -$2.98M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.